Psychedelic Landscape – Request for Feedback

For the past six years, Blossom has tracked all psychedelic research and distilled the findings for researchers, clinicians and the curious. Along the way, we noticed a glaring gap: knowing what the science says is only half the story—understanding who can turn that science into real-world impact is the other half. Today, we are closing that gap with the first public draft of our Psychedelic Landscape Map.

The map plots the full ecosystem at the stakeholder (organisation) level, from venture funds to harm-reduction hotlines. Eight top-level categories are the core of the landscape:

1. Adjunct Industries
2. Care Delivery & Facilitation
3. Community & Culture
4. Funding & Investment
5. Government, Policy & Advocacy
6. Media, Education & Engagement
7. Research, Drug Development & Manufacturing
8. Training & Credentialing

Inside each category, sub-sections capture the diversity of activity: ballot-initiative strategists sit alongside national regulators; telehealth start-ups appear next to indigenous retreat centres. Every stakeholder is tagged with relevant metadata (e.g. country, legal status, substance focus, clinical stage, and more) so that users of the landscape map can filter and drill down with precision.

Why a Landscape Map?

A clear map reveals bottlenecks—underfunded clinical stages, neglected training pathways, and regions without accredited facilitators—and highlights where collaboration or capital would have the greatest impact. By publishing the draft openly, we invite researchers, investors, practitioners, and community leaders to test our assumptions and identify any blind spots.

This is a living document. We will iterate continuously, add new entities, and fold in your suggestions. If you spot an omission, a misclassification, or have data that strengthens a section, tell us. Email your feedback to floris@blossomact.com and we will respond, amend, and credit substantive contributions in the next release.

The full draft map appears directly below this post—scroll down, explore, and let us know what you think. Together, we can turn promising research into accessible, effective psychedelic care.

Landscape Draft

Note: The order of these categories is alphabetical. The final map will be visual, interactive, and non-hierarchical.

Adjunct Industries

This category covers the array of support services and complementary industries that enhance and enable the functioning of the psychedelic ecosystem. It spans legal, technological, and advisory sectors that facilitate operations, compliance, and innovation.

• Legal, Regulatory & Compliance
  Services providing expert guidance on navigating legal challenges and complying with evolving regulatory frameworks.
  • Regulatory Affairs: Expertise in managing compliance with health and safety regulations.
  • Policy and Advocacy: Consulting on the interpretation and impact of policy changes in the psychedelic sector.
  • Intellectual Property: Legal advice for protecting innovations through patents and trademarks.
  • ABS Traceability Tech & Third-Party Auditors: Track material provenance, flag permit expiries, and generate compliance certificates for importers, CROs, and pharma.
  • Compliance Consulting: Expert advice ensuring that all practices adhere to legal, ethical, and regulatory standards.
    
• Psychedelic Healthcare Implementation
  Stakeholders who generate economic evidence, assess value, and design pathways to integrate psychedelic therapies into mainstream health systems.
  • Health Technology Assessment Agencies
    Governmental bodies that critically appraise clinical and economic evidence to make coverage and pricing recommendations.
  • Health Economists
    Experts modeling cost–effectiveness, budget impact, and value-based pricing to inform payer and policy decisions for psychedelic treatments.
  • Payer & Reimbursement Stakeholders
    Specialists who develop coverage policies, negotiate formulary placement, and streamline claims processes for new therapies.
  • Clinical Guideline Development Groups
    Multi-stakeholder committees that synthesise evidence into practice guidelines, dosing protocols, and care pathways for psychedelic interventions.
    
• Technology, Data, & Software Platforms
  Innovative tools and platforms that support the technical and operational aspects of psychedelic research, delivery, and administration.
  • Drug Delivery: Technologies focused on improving methods to administer psychedelic treatments.
  • Neurotechnology: Devices and systems that monitor or modulate brain activity to support treatment.
  • Digital Therapeutics: Software-driven interventions designed to complement or enhance psychedelic therapies.
  • Data Analytics: Platforms offering insights through big data and analytics tools.
  • Artificial Intelligence: AI solutions that optimise research, diagnostics, and treatment personalisation.
    
• Consultancy & Advisory Services
  Professional services offering strategic, operational, and compliance guidance to organisations navigating the psychedelic landscape.
  • Strategic Consulting: High-level advice on market positioning, competitive analysis, and long-term growth planning.
  • Operational Consulting: Support on streamlining processes, capacity building, and improving day-to-day performance.
    

• Creative & Design Services
  Creative and strategic design services shape how psychedelic organisations present themselves, communicate values, and create emotionally resonant experiences. These firms and individuals help bring psychedelic ideas to life through branding, storytelling, immersive media, and spatial or experiential design.
  • Branding, Identity & Strategy: Firms that create, evolve, and communicate the core identity of psychedelic organisations—from positioning and naming to visual design systems.
  • Marketing, Communications & Public Relations: Groups that craft and amplify public narratives around psychedelics, combining media know-how with sector fluency.
  • Experience & Environment Design: Studios focused on designing intentional environments, physical spaces, and sensorial experiences that support therapeutic, communal, or spiritual objectives.
  • Digital, Motion & Immersive Media: Designers and technologists building psychedelic-aligned digital touchpoints, from websites and apps to immersive art installations and VR.
  • Independent & Boutique Creative Practitioners: Freelancers and micro-studios offering specialised creative services that often blend disciplines—branding, copywriting, illustration, digital art, and consulting.

Care Delivery & Psychedelic Facilitation

This section addresses the myriad ways in which psychedelic therapies are administered and integrated into patient care, encompassing both traditional clinical settings and alternative, community-based approaches.

• Traditional Clinical Services
  Conventional healthcare delivery channels providing structured and regulated psychedelic treatment.
  • Outpatient Clinics: Facilities offering scheduled psychedelic treatment without overnight stays.
  • Hospitals: Institutional settings that may incorporate psychedelic therapies into broader mental health services.
  • Telehealth Platforms: Online systems facilitating remote consultation and therapy.
  • Residential Centres: Environments where patients receive intensive, immersive treatment over an extended period.
    
• Practitioner Roles
  The diverse range of professional roles involved in the delivery of psychedelic therapies.
  • Pharmacists: Medication specialists ensuring the proper preparation and management of psychedelic treatments.
  • Therapists: Mental health professionals providing psychotherapeutic support throughout the treatment process.
  • Nurse Practitioners: Advanced practice nurses who often have prescriptive authority and direct patient care responsibilities.
  • Psychiatrists: Medical doctors with specialised training in mental health who prescribe and manage psychiatric treatments.
  • Licensed Social Workers: Professionals offering counselling and social support alongside clinical care.
  • Medical Support: Support staff, including nurses, care coordinators, and technicians, who assist in treatment delivery.
  • Peer Support Specialists: Individuals with personal recovery experience who provide guidance and support to patients.
    
• Alternative, Spiritual & Facilitation Models
  Non-medical, spiritual approaches, and other facilitators who guide preparation, session support, and integration outside formal clinical settings.
  • Faith-Based Providers: Organisations providing treatment through religious or spiritual frameworks.
  • Indigenous Providers: Groups honouring traditional and cultural methods rooted in indigenous practices.
  • Spiritual Providers: Facilitators who merge therapeutic techniques with spiritual or holistic approaches.
  • Non-Traditional Access Services: Informal networks that offer alternative routes to treatment outside conventional healthcare systems.
  • Retreats: Organised, often immersive, sessions providing therapeutic environments away from traditional clinical settings.
  • Guides & Facilitators
    Individuals who provide one-on-one or small-group preparation, in-session support, and integration services without formal licensure.
  • Coaches: Professionals who offer guidance, preparation, and integration support as part of the therapeutic process.

Community & Cultural Stakeholders

This category encompasses the grassroots individuals and collectives who steward ancestral knowledge, mobilise communities around safe use, and advocate for equitable access and cultural respect in the psychedelic field.

• Wisdom Keepers & Elders
  Custodians of intergenerational knowledge, ceremonial protocol, and ethical frameworks for plant medicines.
  • Elders: Elders who transmit protocols for safe, meaningful ceremonies.
• Indigenous Community Members & Traditional Practitioners
  Sovereign stewards of native psychedelic species, safeguarding biocultural heritage and rights.
  • Healers & Shamans: Sangomas, curanderos, ayahuasca maestros, and other lineage-based practitioners.
    Biocultural Preservation: Communities and organisations negotiating benefit-sharing, land rights, and protection of traditional knowledge.
• Representatives & Rights-Holders
  Customary or statutory community authorities (tribal councils, village assemblies, traditional chiefs) that collectively own or steward genetic resources/TK and hold the legal power to grant or withhold access, give FPIC, and negotiate benefit-sharing.
  • Indigenous Peoples & Local Community Authorities (IPLC-As): Customary councils, tribal governments, and other collective bodies that hold sovereign decision-making power over genetic resources and TK, grant FPIC, and negotiate benefit-sharing on behalf of their members.
• Activists & Social Justice Advocates
  Grassroots leaders driving legal reform, reparative justice, and inclusive policy.
  • Decriminalization Campaigners: Coalitions organising ballot initiatives, legislative lobbying, and public demonstrations.
  • Equity & Reparations Networks: Groups addressing disproportionate harms from prohibition and ensuring benefits flow back to affected communities.
  • Civil-Society & Ethical-Trade NGOs: Non-profits that train communities, broker equitable MATs, and watchdog corporate/academic users of biodiversity.

Funding & Investment

This category encompasses all forms of financial support flowing into the psychedelic sector. It includes private funding, philanthropic contributions, and government-backed investment, each of which fuels innovation, research, and commercial expansion in the field.

• Investors
  Institutions and individuals offering capital to early-stage and growing companies within the ecosystem.
  • Angel Investors: Early-stage private investors providing seed capital.
  • Venture Capital: Firms investing in growth-stage companies.
  • Institutional Investors: Large-scale investors such as banks, pension funds, or insurance companies.
  • Social-Impact Investors: Investors seeking both financial returns and positive societal impact.
    
• Foundations & Philanthropy
  Nonprofit organisations and donors that allocate funds to support research, education, and community development.
  • Traditional Foundations: Established organisations offering grants from long-standing endowments.
  • Psychedelic-Specific Foundations: Organisations dedicated exclusively to advancing the field of psychedelics.
  • Grant-Making Organisations: Entities specifically set up to award research grants and project funding.
    
• Government Funding
  Financial support provided by public sector bodies through various programs designed to boost innovation in psychedelic science and industry.
  • Grants, Subsidies & Contracts: Public funding mechanisms such as research grants, subsidies, or service contracts.
  • Direct Investments & Incentives: Government-led investments, tax breaks, or incentives to stimulate business growth.

Government, Policy & Advocacy

This category captures the public sector and civil society efforts to shape policy, enforce regulations, and advocate for reforms within the psychedelic landscape. It emphasises both top-down government interventions and bottom-up advocacy initiatives.

• Government
  Regulatory bodies and public institutions that establish, enforce, and oversee policies pertaining to psychedelic therapies.
  • Federal Agencies: National-level bodies that implement overarching health and regulatory standards.
  • National Health Bodies: Organisations tasked with setting national priorities for health policy and research.
  • State & Local Agencies: Sub-national institutions responsible for localised implementation and enforcement of psychedelic policies.
    
• Advocacy
  Grassroots and organised efforts aimed at driving policy change, ensuring equitable access, and promoting public awareness of psychedelic therapies.
  • Patient Advocacy Organisations: Groups that represent patient interests in policy debates and regulatory reforms.
  • Industry Lobbyists: Entities that work to influence legislative processes in favour of the psychedelic industry.
  • Social Justice & Policy-Focused Advocacy Groups: Organisations committed to ensuring that policy changes benefit diverse populations and address inequities.
  • Ballot Initiatives & Policy Change Campaigns: Campaigns that leverage direct democracy to enact legislative and regulatory reforms.
• Regulation & Enforcement
  Government-mandated bodies—National Focal Points, Competent National Authorities, customs and environmental “checkpoints”—that issue ABS permits, verify FPIC/MAT, and police cross-border movement of genetic resources under the Nagoya Protocol.
  • ABS National Focal Points (NFPs) & Competent National Authorities (CNAs): Government-designated offices that issue access permits, verify FPIC/MAT, and act as the primary checkpoints for Nagoya-Protocol compliance, linking provider countries with foreign users of genetic resources.
  • ABS Compliance & Monitoring Bodies: Customs, border, and environmental-enforcement units that police international shipments, inspect research facilities, and flag non-compliant material flows. (“Checkpoints” under Art. 17 NP).
• Real-World Data & Evidence Collection
  Organisations collecting, curating, and analyzing post-approval and program-level data on safety, efficacy, and patient outcomes for psychedelic therapies.
  • Post-Market Safety Registries: Databases tracking adverse events and compliance with risk-mitigation plans for approved psychedelic treatments.
  • Patient-Reported Outcome Platforms: Systems aggregating patient experience and quality-of-life metrics outside of controlled trials.
  • State Program Monitoring: Data collection initiatives mandated by state-regulated therapeutic programs to assess real-world impact and adherence.
  • REMS Administrators: Entities contracted to oversee regulators’ Risk Evaluation and Mitigation Strategies for compounds like Spravato.

Media, Education & Engagement

This category includes all channels of communication, education, and public engagement surrounding psychedelics. It spans traditional media, digital platforms, and community outreach aimed at increasing public understanding and safety.

• Educational Platforms & Resources
  Tools and resources designed to educate the public and professionals about psychedelics, ranging from academic texts to community-driven materials.
  • Digital Forums: Online discussion boards and communities for sharing ideas and resources.
  • Online Resources: Websites, repositories, and e-learning modules providing up-to-date information.
  • Academic Publications: Peer-reviewed journals and research papers disseminate scholarly findings.
  • Referral Services: Systems that connect individuals with appropriate educational or treatment resources.
  • Public Education Groups: Organisations focused on community-level education and awareness initiatives.
    
• Media & Communication
  The outlets and platforms that disseminate news, analysis, and commentary on psychedelics, facilitating public dialogue and discourse.
  • Traditional Non-Psychedelic Media: Mainstream media outlets that occasionally cover psychedelic topics within broader contexts.
  • Psychedelic News, Blogs & Analysis: Specialised media focusing on dedicated news coverage and expert commentary on the field.
  • Podcasts: Audio programs that discuss trends, research, and personal experiences related to psychedelics.
  • Conferences & In-Person Events: Organised gatherings that foster networking, idea exchange, and public education.
    
• Community Engagement & Harm Reduction
  Efforts geared toward direct community involvement, promoting safe practices, and providing peer support to minimise risks associated with psychedelic use.
  • Local Meetup Groups & Community Collectives: Grassroots groups that gather to share experiences and offer mutual support.
  • Workshops & Community Outreach: Educational and interactive events aimed at increasing local awareness and safe practices.
  • Crisis Intervention Services & Hotlines: Support systems designed to provide immediate assistance during adverse psychedelic experiences.
  • Harm Reduction Initiatives: Programs focused on minimising risks and promoting safe use through informed strategies.
  • Peer-Led Programs: Initiatives run by individuals with lived experience to support and guide community members.

Research, Drug Development & Manufacturing

This broad category covers the scientific and technical journey from discovery to commercial production of psychedelic therapies. It bridges basic research, translational studies, clinical development, and industrial-scale manufacturing.

• Academic & Non-Profit Research
  Research conducted by educational institutions, independent groups, and policy think tanks dedicated to advancing our understanding of psychedelics.
  • Universities and Colleges: Traditional educational institutions with dedicated research programs.
  • Specialised Academic Departments and Institutes: Focused units within universities that concentrate on specific aspects (e.g., neuroscience, pharmacology).
  • Independent Academic Research Groups: Smaller, autonomous groups conducting innovative studies.
  • Think Tanks: Policy-focused organisations that drive research debates and inform strategic decisions.
  • Bioethicists & Ethnobotanists: Experts studying ethical implications and indigenous knowledge of psychedelics.
  • Collaborative Research Consortia: Networks that pool resources among various research entities.
  • Data Repositories & Centralised Registries: Platforms for aggregating and sharing research data.
    
• Company-Led Drug Development & Commercialisation
  The private sector’s efforts to translate scientific findings into therapeutic products ready for clinical and market use.
  • Early-Stage Translational Research (Pre-Clinical): Research transitioning basic science into candidate therapies through mechanistic studies and safety profiling.
  • Clinical Research & Pipeline Products: Organisations with ongoing trials and the development of drug candidates that have entered human testing.
  • Commercialised Products & Marketed Therapies: Approved and market-ready treatments.
    
• Pharmaceutical Manufacturing
  The industrial aspect responsible for producing psychedelic compounds and ensuring quality and compliance throughout the supply chain.
  • Established Manufacturers: Traditional companies with large-scale production capabilities.
  • Psychedelic-Focused Manufacturers: Firms specialised in producing psychedelic substances.
  • Lab Testing, Quality Control & Production Standards: Organisations oversee product quality, safety tests, and regulatory adherence.

Training & Credentialing

This category builds the human capital necessary for the safe and effective delivery of psychedelic therapies. It covers both the educational pathways and the regulatory processes that credential practitioners.

• Formal / Academic Training
  Structured education and training provided by accredited institutions to develop foundational expertise and professional qualifications.
  • University Programs: Degree-level programs and courses within higher education institutions.
  • Accredited Courses: Formal programs that meet standards set by accreditation bodies.
    
• Informal / Self-Development Programs
  Educational initiatives designed for personal growth and supplementary learning outside traditional academia.
  • Online Self-Paced Courses: Pre-recorded, modular courses accessible at any time.
  • Interactive Online Courses: Real-time, instructor-led sessions with opportunities for participant engagement.
    In-Person Experiential Learning: Workshops and retreats offering hands-on, immersive learning experiences.
    
• Credentialing
  The systems and institutions that certify, license, and ensure the continuing education of professionals within the psychedelic field.
  • Regulatory & Licensing Agencies: Bodies that set and enforce practice standards and licensure requirements.
  • Licensing Courses: Programs specifically designed to meet regulatory criteria and support practitioners in obtaining licenses.

Thank you for reading the current draft of the landscape map. Please share your feedback with us at floris@blossomact.com.